Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
26 sept. 2022 08h00 HE
|
Surrozen, Inc.
Results highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth into physiological...
Surrozen Reports Second Quarter 2022 Financial Results
11 août 2022 08h00 HE
|
Surrozen, Inc.
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in Q2 continue to validate Wnt modulation for...
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
13 juin 2022 08h00 HE
|
Surrozen, Inc.
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1First part of two-part Phase 1 trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., June...
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
24 mai 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
18 mai 2022 08h00 HE
|
Surrozen, Inc.
SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP) bi-specific antibodyFirst part of three-part Phase 1/1b trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE)...
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)
16 mai 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair...
Surrozen Reports First Quarter 2022 Financial Results
11 mai 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
05 mai 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
02 mai 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
24 mars 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...